Latest news and press releases about KALA BIO, Inc. (KALA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R.
Price
| Price | $0.52 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | -1.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -222.32% |
| Return on Invested Capital | -232.05% |
| Return on Assets | -95.26% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABP · AIM · CANF · ENSC · IBO · KTTA · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KALA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks